Want to see NL:PHARM full AI Analyst Report?
PHARM Stock Chart & Stats
€1.10
€0.03(2.36%)
At close: 4:00 PM EDT
€1.10
€0.03(2.36%)
Day’s Range― - ―
52-Week Range€0.83 - €1.82
Previous CloseN/A
Volume3.39M
Average Volume (3M)19.18M
Market Cap
€673.10M
Enterprise Value€934.02
Total Cash (Recent Filing)€158.25M
Total Debt (Recent Filing)€126.73M
Price to Earnings (P/E)76.9
Beta0.86
Next Earnings
Nov 05, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding707,781,250
10 Day Avg. Volume15,825,784
30 Day Avg. Volume19,178,179
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)3.72
Price to Sales (P/S)2.74
P/FCF Ratio20.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€390.63M
Bulls Say, Bears Say
Bulls Say
Joenja Commercial MomentumSustained high-single to high-double-digit growth in Joenja reflects durable adoption for a chronic, specialty therapy. Geographic launches (UK live, Germany launched, Japan planned) and pediatric label work expand addressable market and create recurring revenue that supports multi-quarter visibility and pipeline prioritization.
Very High Gross MarginsConsistently very high gross margins provide structural profitability leverage: incremental sales largely flow to the bottom line, enabling the company to sustain investment in R&D while generating operating cash. This margin profile enhances resilience to price pressure and supports long-term funding of pipeline programs.
Improving Balance Sheet LeverageMeasured deleveraging and an improved equity base reduce solvency and refinancing risks. Positive ROE and manageable debt-to-equity provide the company durable financial flexibility to fund incremental R&D and commercial expansion over the next several quarters without immediate capital raises.
Bears Say
Revenue/guidance CutA meaningful downward guidance revision reflects structural near-term commercial headwinds, notably RUCONEST share loss to a new oral competitor and international withdrawal impacts. This reduces revenue visibility over coming quarters and limits free-cash-flow upside until share and volume trends stabilize.
Cash Flow VolatilityDespite returning to positive FCF in 2025 and TTM, recent quarter-level operating outflows and material quarter-to-quarter swings show working-capital and inventory sensitivity. With planned incremental R&D spend and modest cash buffers, the company faces a durable funding and execution risk over the next several quarters if cash generation weakens.
Manufacturing Inventory And Site ProvisionsInventory write-downs and planned site closures signal operational and supply-chain issues that can persist beyond a single quarter. Such impairments reduce usable inventory, raise COGS risk and may require further capital or operational fixes, negatively impacting gross margin sustainability and supply continuity until resolved.
Pharming Group News
PHARM FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was €0.83 and its highest was €1.82 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is €673.10M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Nov 05, 2026 which is in 85 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Jul 30, 2026. The company reported €0.002 earnings per share for the quarter, missing the consensus estimate of €0.005 by -€0.003.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Overvalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 707,781,250 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of €0.002 in its last earnings report, missing expectations of €0.005. Following the earnings report the stock price went down -20.31%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in NL:PHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
PHARM Company Deck
PHARM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful commercial and clinical positives—most notably strong Joenja growth, resilient RUCONEST patient metrics, and near‑term clinical catalysts—against tangible near‑term headwinds including a $30M revenue guidance reduction, RUCONEST year‑over‑year sales decline, manufacturing inventory impairments, and operating cash outflows. Management emphasized cost discipline, maintained positive operating profitability in the quarter, and outlined multiple growth levers (pediatric and geographic expansion for Joenja, two Phase II readouts in Q4, and a 2027 pivotal readout for napazimone). Given the balance of clear growth drivers and pipeline upside against notable short‑term financial and operational challenges, the tone is constructive but cautious.View all NL:PHARM earnings summaries